CytomX Therapeutics (CTMX) Return on Capital Employed (2015 - 2026)
CytomX Therapeutics' (CTMX) quarterly Return on Capital Employed came in at 29.2% in Q1 2026, down 8982.0% YoY from 0.33% in Q1 2025, and down 41.39% on a QoQ basis from 20.65% in Q4 2025.
CytomX Therapeutics (CTMX) Return on Capital Employed (2015 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 12 years of Return on Capital Employed data on file, last reported at 29.2% in Q1 2026.
- Quarterly Return on Capital Employed fell 8982.0% year-over-year to 29.2% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.2% (down 8982.0% YoY) and the FY2025 annual result came in at 25.01%, down 5816.0% from the prior year.
- Return on Capital Employed retreated to 29.2% in Q1 2026, from 20.65% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 60.62% in Q1 2025 to a low of 111.25% in Q4 2022.
- A 5-year average of 18.7% and a median of 20.65% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 9987 bps — and 2026, when it slumped 8982 bps.
- Tracing CTMX's Return on Capital Employed over 5 years: stood at 111.25% in 2022, then soared by 90 bps to 11.67% in 2023, then soared by 587 bps to 56.83% in 2024, then tumbled by 136 bps to 20.65% in 2025, then sank by 41 bps to 29.2% in 2026.
- The last three Return on Capital Employed figures came in at 29.2% (Q1 2026), 20.65% (Q4 2025), and 18.5% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -26.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.38% |
| Mar 31, 2026 | -29.20% |
| Dec 31, 2025 | -20.65% |
| Sep 30, 2025 | 18.50% |
| Jun 30, 2025 | 44.21% |
| Mar 31, 2025 | 60.62% |
| Dec 31, 2024 | 56.83% |
| Sep 30, 2024 | 22.46% |
| Jun 30, 2024 | 19.67% |
| Mar 31, 2024 | 22.23% |
| Dec 31, 2023 | -11.67% |
| Sep 30, 2023 | -22.50% |
| Jun 30, 2023 | -59.88% |
| Mar 31, 2023 | -77.64% |
| Dec 31, 2022 | -111.25% |
| Sep 30, 2022 | -105.92% |
| Jun 30, 2022 | -69.67% |
| Mar 31, 2022 | -54.05% |
| Dec 31, 2021 | -41.82% |
| Sep 30, 2021 | -32.95% |